Merck built a wall of patents that keeps a cancer drug's price – and its profits – high. Hospitals often add to the cost for ...

A cross-border investigation by DW and ICIJ reveals how pricing and patents helped turn a life-saving medicine into one of ...

Merck & Co.'s Keytruda in the U.S. starts at $12,000 for a 200 mg dose. Costs go up from there based on the insurer, provider ...

Merck (NYSE:MRK) received expanded EU approval for KEYTRUDA-based regimens in platinum-resistant ovarian cancer, making it ...

Keytruda's first approval by US FDA came in the year 2014 for advanced skin cancer. Now, the immunotherapy drug is being used ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that KEYTRUDA® (pembrolizumab), in ...

Keytruda, an immunotherapy drug, is transforming cancer treatment in India by helping the immune system fight cancer cells.

Keytruda is approved by the Drug Controller General of India (DCGI) for multiple cancer types. As of recent approvals, it ...

Keytruda, manufactured by the US-based Merck & Co, is an immunotherapy drug that has become one of the world’s best-selling ...

In India, Keytruda is approved by the Drug Controller General of India (DCGI) for multiple cancer types. As of recent ...

KEYTRUDA monotherapy now approved as neoadjuvant treatment, continued as adjuvant treatment combined with radiotherapy with or without concomitant cisplatin then as monotherapy Based on results of ...

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase 3 KEYNOTE-B15 trial (also known as EV-304) in ...